Predictive Oncology Inc. CEO Provides Updates on Subsidiaries, Highlights Recent Milestones and Near-Term Goals
October 27 2020 - 8:30AM
via NetworkNewsAudio — Predictive Oncology Inc. (NASDAQ: POAI)
today announces that its chief executive officer, Carl Schwartz,
has been featured in an exclusive audio interview with
NetworkNewsWire (“NNW”), a financial news and content distribution
company and one of 50+ brands in the InvestorBrandNetwork (“IBN”).
During the interview, Schwartz provided an update on the company’s
recent milestones and near-term goals following the October release
of his Letter to Shareholders. In particular, Schwartz put a focus
on the company’s subsidiaries: Skyline Medical, TumorGenesis,
Soluble Biotech and Helomics.
The broadcast can be heard at The NetworkNewsAudio Interviews
Podcast.
After offering some brief insight into the operations of Skyline
Medical, Schwartz turned his attention toward TumorGenesis.
“TumorGenesis is an interesting company. The whole purpose of it
was to develop a lab media to replace rats and mice in the
scientific industries and in the testing of tumors,” he stated in
the interview. “They have developed the first one, which is ovarian
cancer, and the results of this are that this media, which, as I
said, replicates the body, fools the tumor into thinking it’s still
in the body. Its reactions are very, very similar to what it would
have done had it been in the body. Now, the next step is to get it
positioned to manufacturers and getting the kits out so people can
use it. That’s coming along handsomely. It’ll take a little time to
get all this put in place, but the optimism is there, and the
results are wonderful. We’re very excited.”
Schwartz then discussed Predictive Oncology’s newest subsidiary.
“[Soluble Biotech] is our newest acquisition. These are two labs
that we put together, and we moved them now into a research park.
We quadrupled the space that they have, and they have the latest in
equipment,” he continued. “The technology used by Soluble is
proprietary. These machines that we have were developed some time
ago and are the only machines of their kind. In the determination
of solubility of products, they work wonders in that area. We
expect, going forward, that they’ll get a number of contracts.”
Looking ahead to the balance of 2020 and beyond, Schwartz put a
spotlight on the company’s remaining subsidiary, Helomics.
“I think the fourth quarter, obviously, will be eventful. We
have positioned Helomics to compete in the marketplace,” he said.
“The original basis of Helomics… was that physicians or hospitals
would send their tumors to this company and they would test the
tumors with the known therapies of the day… In that process,
[Helomics] accumulated over 150,000 tumors covering over 137
different cancers… That database is the largest of its kind in the
world… With that data, and the fact that we’ve sequenced these
tumors, we have shown that we can provide quality information to
anyone who needs it. There’s a lot going on at Helomics. We think
we’ve validated the company. We’ve got assets that are
one-of-a-kind in the world, and we think we are on our way to where
we wanted to be when we first purchased this company a couple of
years ago.”
Please listen to the full interview with Predictive Oncology CEO
Carl Schwartz at https://nnw.fm/e0fDA.
About Predictive Oncology Inc.
Predictive Oncology (NASDAQ: POAI) operates through three
segments (domestic, international and other), which contain four
subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble
Biotech.
Helomics applies artificial intelligence to its rich data
gathered from patient tumors to both personalize cancer therapies
for patients and drive the development of new targeted therapies in
collaborations with pharmaceutical companies. TumorGenesis Inc.
specializes in media that help cancer cells grow and retain their
DNA/RNA and proteomic signatures, providing researchers with a tool
to expand and study cancer cell types found in tumors of the blood
and organ systems of all mammals, including humans. Skyline Medical
markets its patented and FDA cleared STREAMWAY System, which
automates the collection, measurement and disposal of waste fluid,
including blood, irrigation fluid and others, within a medical
facility, through both domestic and international divisions.
Soluble Biotech is a provider of soluble and stable formulations
for proteins including vaccines, antibodies, large and small
proteins and protein complexes.
For more information, visit the company’s website at
www.Predictive-Oncology.com
About NetworkNewsAudio (NNA)
NetworkNewsAudio (“NNA”) allows you to sit back and listen to
market updates, CEO interviews and a company AudioPressRelease
(“APR”). These audio clips provide snapshots of position,
opportunity and momentum. NNA can assist your company by
cutting through the overload of information in today's market. NNA
brings its Client Partners unparalleled visibility, recognition and
brand awareness. NNA is just one site within our sizable family of
50+ brands within the InvestorBrandNetwork (“IBN”). IBN is a
comprehensive provider of news and original articles; we aggregate
and syndicate this content for much bigger impact. IBN also adds
Press Release Enhancement and a full array of social media
communication solutions and has amassed a collective audience that
includes millions of social media followers. As a multifaceted
financial news and distribution company with an extensive team of
journalists and writers, IBN has the unparalleled ability to reach
a wide audience comprising investors, consumers, journalists and
the general public with an ever-growing distribution network of
5,000+ key syndication outlets across the nation.
For more information, please
visit: www.NetworkNewsAudio.com or The NetworkNewsAudio
News Podcast
Please see full terms of use and disclaimers on the
InvestorBrandNetwork website applicable to all content provided by
IBN, wherever published or
re-published: http://IBN.fm/Disclaimer
Forward-Looking Statements
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended
and Section 21E of the Securities Exchange Act of 1934, as amended.
All forward-looking statements are inherently uncertain as they are
based on current expectations and assumptions concerning future
events or future performance of the company. Readers are cautioned
not to place undue reliance on these forward-looking statements,
which are only predictions and speak only as of the date hereof. In
evaluating such statements, prospective investors should review
carefully various risks and uncertainties identified in this
release and matters set in the company's SEC filings. These risks
and uncertainties could cause the company's actual results to
differ materially from those indicated in the forward-looking
statements.
Corporate Communications
InvestorBrandNetwork (IBN)Los Angeles,
Californiawww.InvestorBrandNetwork.com310.299.1717
OfficeEditor@InvestorBrandNetwork.com
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Predictive Oncology (NASDAQ:POAI)
Historical Stock Chart
From Apr 2023 to Apr 2024